ImmunityBio, Inc., a commercial-stage immunotherapy company trading under the ticker IBRX, released its financial results for the third quarter ended September 30, 2026, alongside updates regarding its clinical pipeline and international regulatory progress.
During the third quarter of 2026, the company recorded net product revenues of $48.7 million, representing an increase of 53% compared to the same period in the prior year. This growth was attributed by management to stronger adoption among urologists in the United States and favorable market access. For the first nine months of 2026, cumulative net product revenue reached $143.6 million, marking a 92% increase year-over-year. As of September 30, 2026, ImmunityBio reported cash, cash equivalents, and marketable securities totaling $334.3 million.
Financial performance metrics for the quarter included research and development expenses of $71.5 million, compared to $51.2 million in the third quarter of 2025. Selling, general, and administrative expenses rose to $54.0 million from $36.3 million. Other expense, net, increased to $106.6 million, largely driven by non-cash adjustments related to the fair value of related-party convertible notes, warrant liabilities, and derivative liabilities linked to fluctuations in common stock price, as well as higher interest expenses on revenue interest liabilities. Consequently, the net loss attributable to common stockholders widened to $184.6 million for the quarter, compared to $67.3 million in the third quarter of 2025. Adjusted net loss attributable to common stockholders on a non-GAAP basis was $97.9 million.
Regulatory milestones highlighted by the company include the U.S. Food and Drug Administration's approval on October 14, 2026, of a supplemental Biologics License Application expanding the indication for ANKTIVA in combination with Bacillus Calmette-Guérin to include adult patients with BCG-unresponsive non-muscle invasive bladder cancer with high-grade papillary-only tumors. Additionally, the company noted that Cohort A of the QUILT-2.005 trial met its primary endpoint in November 2026, keeping it on track to submit a supplemental Biologics License Application for BCG-naïve non-muscle invasive bladder cancer patients in the fourth quarter of 2026. International developments included ANKTIVA's approval in Israel for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, bringing total global approvals to 35 across six regulatory jurisdictions, as well as the administration of the first commercial treatments to patients in Europe.
